AstraZeneca's Breast Cancer Drug Misses Target in Critical Trial

AstraZeneca failed to achieve the expected results in a critical clinical trial for its breast cancer treatment. The company's drug did not meet the primary endpoint of the study. The trial's failure is seen as a significant setback for AstraZeneca's research and development efforts in oncology. The drug had shown promise in terms of efficacy in breast cancer patients, but the results did not meet this expectation. The company stated that it will analyze the data from the trial in detail and shape its future strategies accordingly. AstraZeneca announced that it will continue its work on other cancer types. This development is being closely watched by investors. In the pharmaceutical sector, clinical trial results can have significant impacts on companies' share performance and market value. Not investment advice.

📊 AZN — Piyasa Yorumu

▼ down · 60%

AstraZeneca's breast cancer drug missing its target in a critical trial could create negative news flow for the stock in the short term. Technical indicators are giving mixed signals: RSI is neutral at 54, MACD is in negative territory and below the signal line, but the price is slightly above the SMA20. The last close at 160.17 is very close to the SMA50 (160.75); if it falls below this level, the decline could accelerate. The impact of the news may be limited because the market may have already priced in such news in the pharmaceutical sector overall. Nevertheless, short-term selling pressure is likely.

RSI 14

54.4

MACD

-0.21

24h Δ

0.04%

📊 GOOGL — Piyasa Yorumu

■ neutral · 60%

The news headline is related to AstraZeneca and has no direct connection to GOOGL stock; therefore, its impact on GOOGL is expected to be limited. Technical indicators are giving mixed signals: RSI at 56 is in neutral territory, MACD is above the signal line (positive), but the price is just below the 50-day moving average (336.92) and above the 20-day average (334.11). The change over the last 24 hours is only 0.10%, indicating a sideways trend. Due to the news being outside the sector, directional uncertainty for GOOGL continues; a neutral outlook prevails in the short term.

RSI 14

55.9

MACD

1.03

24h Δ

0.10%

Canlı Grafikler